Following these proceedings, UBS downgraded its Coherus Biosciences Inc [CHRS] rating to a Neutral from a a Buy in a research note published on August 16, 2024; the price target was decreased to $1.50 from $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. Maxim Group also remained covering CHRS and has decreased its forecast on November 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on July 24, 2023. It rated CHRS as “a Buy”.
Price Performance Review of CHRS
On Monday, Coherus Biosciences Inc [NASDAQ:CHRS] saw its stock jump 5.30% to $1.02. Coherus Biosciences Inc shares have fallen nearly -26.09% since the year began. Nevertheless, the stocks have fallen -54.26% over the past one year. While a 52-week high of $2.43 was reached on 01/06/25, a 52-week low of $0.66 was recorded on 04/09/25. SMA at 50 days reached $0.9565, while 200 days put it at $1.1502.
Levels Of Support And Resistance For CHRS Stock
The 24-hour chart illustrates a support level at 0.9732, which if violated will result in even more drops to 0.9264. On the upside, there is a resistance level at 1.0634. A further resistance level may holdings at 1.1068. The Relative Strength Index (RSI) on the 14-day chart is 52.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0232, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 57.71%. Stochastics %K at 31.44% indicates the stock is a holding.
The most recent change occurred on May 01, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
